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Summary: The effect of glucose on drug-promoted induction of porphyrin synthesis was studied in chick
embryo liver cell culture with and without the addition of exogenous -aminolaevulinic acid (ALA). Induction
of ALA synthase was abolished by haemin or glucose. Less than 10% 0f porphobilinogen is converted into
protoporphyrin. Protoporphyrin synthesis cannot be enhanced by high ALA concentrations. The conversion
of exogenous ALA into porphyrins decreases with increasing concentrations of ALA from 0.1 to 2.0 mmol/1,
whereas porphobilinogen accumulates, thus reflecting the rate limiting function of Uroporphyrinogen synthase,
which is not influenced by glucose. This needle-eye-like function of Uroporphyrinogen synthase within the
porphyrin biosynthetic chain explains the urinary increase of ALA and porphobilinogen in the acute phase
of variegate and coproporphyria, similar to that in acute intermittent porphyria.
i
* The "glucose effect" was also investigated in vivo in humans in 32 courses of hereditary acute hepatic
. v porphyrias (acute intermittent porphyria, variegate porphyria, coproporphyria and porphobilinogen synthase
defect porphyria). Patients were treated with high carbohydrate intake (~500 g/24 h), mainly in the form of
glucose infusions. There was a resulting coiisistent and highly significant decrease of porphyrin biosynthesis
metabolites, accompanied by clinical improvement in most of the patients.
"Glucose-Effeki" und limitierende Funktion der Uroporphyrinogen-Synthase auf den Porphyrinstoffwechsel in
der Leberzellkultur in Bezug auf die akuten hepatischen Pörphyrien des Menschen
Zusammenfassung: Die Wirkung von Glucose auf die Arzneimittel-vermittelte Induktion der Porphyrin-
synthese wurde in Hühnerembryo^Leberzellkulturen unter Bedingungen mit endogener und exogener 5-
Aminolävulinsäüre (ALS) studiert. Die Induktion der ALS-Synthase konnte durch Hämin oder Glucose
aufgehoben werden. Wenjger als 10% Porphobilinogen wird in Porphyrine konvertiert. Die Synthese von
Protoporphyrin kann unter hohen ALS-Konzentrationen nicht gesteigert werden. Die Umwandlung exogener
ALS in Porphyrine fällt mit steigender Konzentration der ALS von 0,1 bis 2,0 mmol/1, während Porphobilino-
gen akkumuliert: Hierin spiegelt sich die Umsatz-limitierende Funktion der Uroporphyrinogen-Synthase, die
nicht durch Glucose beeinflußt wird". Die Nadelöhr-ähnliche Funktion der Uroporphyrinogen-Synthase
innerhalb der Porphyrinbiosynthesekette erklärt den Anstieg von ALS und Porphobilinogen im Urin in der
akuten Phase der Porphyria variegata und der Koproporphyrie, welcher demjenigen bei akuter intermittieren-
der Porphyrie ähnlich ist.
Der "Glucose-Effekt" in vitro wurde mit dem in vivo beim Menschen verglichen und bei 32 Verläufen
hereditärer akuter hepatischer Porphyrieii untersucht (akute intermittierende Porphyrie, Porphyria variegata,
. Koproporphyrie und Porphobilinogen-Synthasedefekt-Porphyrie). Die Patienten wurden mit hoher Kohlenhy-
I drataufnahme (^500 g/24 h) behandelt, vorwiegend in Form von Glucose-Infusionen. Die biochemische
Antwort mit einem Abfall der Porphyrinbiosynthese-Metaboliten war folgerichtig und hochsignifikant,
! verbunden mit einer klinischen Besserung bei den meisten Patienten.
J. Clin. Chem. Clin. Biochem. / Vol. 23,1985 / No. 9
506 Doss, Sixcl-Diclrich and Verspohl: "Glucose effect" in hepatocyte culture and in acute hepatic porphyrias
Introduction
The "glucose effect" in experimental allyl-
isopropylacetamide-induced porphyria, which simu-
laled acute intermittent porphyria, was first demon-
strated over 20 years ago by Tschudy's group (1). It
could be shown that the porphobilinogenuric effect
of allylisopropylacetamide is influenced by diet, and
primarily by its carbohydrate and protein content. A
subsequent study concluded that the dietary effect on
changes in porphyrin precursor excretion in patients
with acute intermittent porphyria is related to protein
and carbohydrate content rather than total caloric
content per se (2). δ-Aminolaevulinic acid (ALA) and
porphobilinogen excretion decreased after addition
of carbohydrates to the diet. In a third study by
Marver, Tschudy and coworkers the effect of car-
bohydrate feeding on the ihduction of ALA synthase
in experimental acute porphyria in rats was in-
vestigated, and it was shown that diet is a regulatory
factor in hepajtic porphyrin synthesis in porphyria (3,
4). Administration of carbohydrates to rats markedly
inhibits the induction of ALA synthase. It was then
demonstrated that Symptoms and biochemical
fmdings in variegate porphyria were rapidly reversed
by intravenous glucose application (5). The ob-
servations were explained implying the "glucose
effect" on hepatic ALA synthase. However, ALA
synthase, the key enzyme of haem biosynthesis, is not
the only enzyme subject to the "glucose effect". The
induction of two other enzymes, tryptophan oxy-
genase and tyrosine aminotransferase, is markedly
attenuated following the consumption of glucose (6,
7).
Porphyria precipitated by fasting (8), porphyrinuria
induced by fasting in nonporphyric subjects (9) and
"caloripenic porphyria" (10) were next reported and
i t was suggested that a low-caloric diet or abrupt
reduction in carbohydrate and protein intake may
provoke Symptoms in addition'to elevating urinary
ALA, pyrrol and porphyrin excretion (11, 12).
The acute hepatic porphyrias are essentially reg-
ulatory disorders at the molecular level (13, 14) and
characterized by inherited enzymatic defects at dif-
ferent stages of the haem biosynthetic sequeftce
(fig. 1). The extreme increase of porphyrin precursor
excretion in acute intermittent porphyria, variegate
and coproporphyria (13) can only be explained on
the basis of the secondarily limiting f riction of
uroporphyrinogen synthase (15 — 18). Meanwhile the
rate limiting function of uroporphyrinogen synthase
for the conversion of ALA into protoporphyrin was
proven in homogenates (19) and the "glucose effect"
was demonstrated in liver cell cultures (11, 20—22).
In the present study
1. the "glucose effect" on porphyrin synthesis is com-
pared in vitro and in vivo and
2. the intriguing role of uroporphyrinogen synthase
s a secondary limiting factor is considered in view
of the glucose-mediated repression of coun-
terregulation in acute hepatic porphyrias.
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Fig. 1. Enzyme deficiencies and counterregulation in the acute hepatic porphyrias: acute intermittent porphyria, hereditary
cpproporphyria, porphyria variegata, and porphobilinogen synthase deficiency porphyria. The hereditary enzyme deficien-
cies of porphobilinogen synthase (EC 4.2.1.24), uroporphyrinogen synthase (EC 4.3.1.8), Coproporphyrinogen oxidase
(EC 1.3.3.3), and protoporphyrinogen oxidase (EC 1.3.3.4), lead to a destabilization of the regulatory controi of haem
on the key enzyme of the biosynthetic chain, δ-aminolaevulinic acid synthase (EC 2.3.1.37). Glucose s well s haem
represses δ-aminolaevulinic acid synthase. Decrease of "regulatory liver haem" mairily in the acute phase is followed by
induction of δ-aminolaevulinic acid synthase. The metabolic conversion of high rates of porphobilinogen into porphyrino-
gens is generally limited by the secondary controlling step catalyzed by uroporphyrinogen synthase (Y).
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Experimental and Clinical Investigation
Experimcntal design
Avian embryo liver celfcultures according to the Granick System
(23) were prepared s earlier described (24). Induction of
porphyrin synthesis by meprobamate in the chick embryo liver
cell culture served s positive control. Fof the experiment in
this study, glucose was replaced in Eagle's basal medium by 10
mmol/1 sodium pyruvate (25). After one day the medium was
changed to fresh medium supplemented with glycine (10
mmol/1), insulin (200 Mg/l), glucagon (40 μg/l), and adenosine-3'-,
5'cyclic monophosphate (50 μηιοΐ/ΐ) (Sigma), whieh was shown
to promote the drug-mediated induction (26), Substances listed
in table l were added, and total protoporphyrin of both cells
and medium was measured after 24 h of further incubation.
When the medium was changed, 20 μπιοΐ/ΐ laevulinate (Sigma)
was added to the medium of those cultures intended for the
determination of ALA-S; this laevulinate was added in order
to block porphobilinogen synthase, and thereby prevent the
further metabolism of newly synthesized ALA. The activity of
ALA synthase was determined by the colorimetric method of
Sinclair & Granick (27). In parallel cultures protein was meas-
ured by the Lowry method (28).
In a second series of experiments exogenous ALA was added
in various concentrations (tab. 2) in order to study the limiting
function in uroporphyrinogen synthase and the influence of
glucose on this enzyme under high Substrate conditions orig-
inating from supplemented ALA.
Porphobilinogen was measured after ion exchange and
porphyrins after thin-layer chromatography in combination
with spectrophotometry and spectrophotofluorometry
(29-31).
Pat ients and methods
The approach to the differential diagnosis of acute hepatic
porphyrias in most of the patients compiled in table 3 was
previously described in detail (13). Preliminary diagnoses based
on tests for acute hepatic porphyrias (32) were performed to
initiale early treatment and omission of porphyrinogenic drugs.
ALA and porphobilinogen were isolated by ion exchange chro-
matography (29), and porphyrins and uroporphyrinogen
synthase wefe analysed s described (30, 31, 33). Data on
accuracy and precision of the analytical methods are presented
in foregoing methodical Communications (29, 30).
Most of the patients were admitted to hospitals for intensive
care due to a complex acute porphyria syndrome. Dcpending
on the clinical Situation of the patients, glucose trcatmcnt took
the form of infusions (about 0.3 g/kg · h) or in combination
with a diet rieh in carbohydrates so that 450 to 500g of
carbohydrates per day were rcceived per 70 kg body weight.
Renal elimination of porphyrin precursors and porphyrins was
examined daily during the glucose therapy, and molar con-
version rates of porphobilinogen to porphyrins were calculaled
on the basis of these determinations (tab. 4).
Results
In vi t ro studies in hepatocytes
Meprobamate had formerly been proved to be a
strong inducer (24). Two characteristic parameters of
the inducing process are ALA synthase and pro-
toporphyrin, which is the first and dominant por-
phyrin accumulating under in vitro conditions and
therefore an indicator for the intensity of the in-
duction process. Meprobamate leads to an increase
of ALA synthase (12 fold) and protoporphyrin (18
fold) (tab. 1). Haemin or glucose markedly decrease
the meprobamate-induced elevation of ALA
synthase, porphobilinogen and protoporphyrin. The
"glucose effect" is dose-dependent. A glucose con-
centration of 80 mmol/1 lowers ALA synthase to 33%
and protoporphyrin to 30% of the inducing level.
The corresponding values for haemin (0.01 mmol/1)
are 25% and 15%, respectively (experiment 3, tab. 1).
The porphobilinogen concentration is generally very
low (tab. 1). Calculated from these data, only 2.5%
porphobilinogen equivalents are contained in pro-
toporphyrin (experiment 1). Porphobilinogen in-
creases after induction of ALA synthase sim-
ultaneously with protoporphyrin (experiment 2). But
the conversion of porphobilinogen into porphyrin is
only enhanced by 7%.
Tab. 1. Glucose effect in hepatocytes.
Effect of glucose on the meprobamate-induced δ-aminolaevulinic acid (ALA) synthase, pyrrol and porphyrin biosynthesis
in avian hepatocytes grown in culture. Results are obtained from flve parallel experiments: χ ± SD (Standard deviation).
Experiment
1 ..
2
3
4
5
6
7
8
9
10
11
12
Additions to the media
(mmol/1)
None
Meprobamate (1)
Meprobamate (1) and haemin (0.01)
Glucose (40 or 80)
Glucose (40) and meprobamate (1)
Glucose (80) and meprobamate (1)
Exp. 1 with added ALA (0.1)
Exp. 2 with added ALA (0.1)
Exp. 3 with added ALA (0.1)
Exp. 4 with added ALA (0.1)
Exp. 5 with added ALA (0.1)
Exp. 6 with added ALA (0.1)
ALA synthase
(μπιοΐ/η · g protein)
30 + 10
360 + 80
90 + 30*
28 + 10
240 + 50*
120 + 40*
Porphobilinogen
(μιηοΐ/g protein)
4 ± 2
39 ± 5
26 + 4
5 ± 2
23 + 4
14 + 3
8 ±2
58 ± 6
18 + 4
9 ± 3
18 ± 4
15 ± 3
Protoporphyrin
(nmol/g protein)
25 ± 4
710 ± 60
105 + 20*
22 ± 5
450 ± 35*
210 + 30*
1800 + 180
1920 ± 200
1690 + 190
1950 ± 190
1820 + 240
1700 + 250
Significance (Studenfs t-test) of the difference value marked by * and experiment 2: p < 0.001.
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Exogenous ALA stimulates porphyrin synthesis. The
drug itself and its combination, either with glucose
or haemin, did not significantly infhience pro-
toporphyrin synthesis from added ALA. The con-
version of porphobilinogen into protoporphyrin after
meprobamate-promoted induction and ALA
supplementation (experiment 8) increases up to 13%.
Glucose has no influence on the metabolism of
porphobilinogen.
The conversion of ALA into porphyrin depends on
its concentration up to about l mmol/1 (tab. 2). The
more ALA is offered to hepatocytes, the less will
be transformed into protoporphyrin. As the added
concentration of ALA is increased, its utilization
decreases to 86%, associated with an accumulation
of porphobilinogen. At a concentration of ALA of
2 mmol/1, only ~15% of porphobilinogen is con-
verted into porphyrin. Thus, in porphyrin synthesis
from ALA, protoporphyrin remäins the dominant
component. , ,
Tab. 2. Porphobilinogen and porphyrin biosynthesis from ex-
ogenous -aminolaevulinic acid (ALA) in avian
hepatocyte cuiture (x ± SD; n = 4) without and in
the presence of glucose (40 mmol/1).
ALA
added
(mmol/1)
0.1
0.5
1.0
1.5
2.0
Porphobilinogen
(pmol/g protein)
without with
glucose glucose
7.5 +
28.4 ±
48.3 ±
50.6 ±
54.0 ±
1.6*
3.9*
6.3*
7.0
8.0
7.0
26.1
50.4
47.8
57.0
±
±
±
±
±
1.8
4.3
7.0
9.3
6.5
Protoporphyrin
(nmol/g protein)
without with
glucose glucose
1800 ±
1950 ±
2200 ±
2300 ±
2100 ±
160
200
190
210
190
1700
2100
2050
2150
2000
±
±
±
+
+
180
170
250
160
220
mean values are significantly different at p < 0.001.
Clinical-biochemical studies
High-dose glucose treatnient promotes a marked
decrease of porphyrin precursor and porphyrin ex-
cretion in the three autosomal dominant transmitted
acute hepatic porphyrias (acute intermittent
porphyria, variegate porphyria aEiid coproporphyria).
In 30 patients the decrease in excfetion lies between
66 and 91% of the initial values (tab. 3). In the two
patients with the uncommqn homozygous por-
phobilinogen synthase defect porphyria the decrease
of metabolite excretion was only 50—70%. The bio-
chemical response to glucose usually occurs after 3
to 5 days, äs shown in figure 2, and is associated with
clinical improvement. During the decompensated
latency phase, ALA/porphobilinogen ratios and
copro-/uroporphyrin ratios are < 1; with transition
to a compensated phase, which is the therapeutic
goal, these factors rise > l (flg. 3). This increase in
connection with a drop of metabolites is jüdged äs a
prognostically positive sign.
The change in the hepatic conversion of
porphobilinogen into porphyrins, calculated on the
basis of the urinary molar excretion ratio of
porphobilinogeri and porphyrins, is an essential in-
dicator of the acute porphyria disease düe to the
generally limiting function of uroporphyrinogeii
synthase in the liver and its specific genetic deficiency
in acute intermittent porphyria (33). In the acute
phase of acute intermittent porphyria this factor is
decreased below the level of controls (tab. 4) due to
a synergistic effect of boüfthe limiting function and
inherited deficiency öf uroporphyrinogen synthase
(fig. 1). In variegate and coproporphyria the con-
Tab. 3. Effect of glucose on urinary excretion of -aminolaevulinic acid (ALA), porphobilinogen (PBG) and porphyrins (POR)
in 32 patients with acute intermittent porphyria, variegate porphyria, hereditary coproporphyria and porphobilinogen
synthase defect porphyria.
Diagnosis and cases
Acute intermittent porphyria
(n = 15)
Hereditary coproporphyria
(n = 10)
Variegate porphyria
(n = 5)
Porphobilinogen synthase
defect porphyria (n = 2)
Glucose
kJ/24 h
(days)
7600 (13)
7200 (9)
8400 (24)
6000 (6)
Metabolites ( /24 h)
before treatment after treatment
ALA PBG POR ALA PBG POR
846 787 9 219* 265* 3*
318 405 9 59* 36* 2*
541 429 7 61* 21* 2*
3520 9 7 1780* 3* 3*
Drop of excretion
% % %
ALA PBG POR
74
81
89
49
66
91
95
67
67
78
71
57
Upper limit 49 7.5 0.2
* Significance between values before and after treatment: p < 0.001 (Student*$ t-test). * *
J. Clin. Chem. Clm. Biochem. / Vol. 23,1985 / No. 9
Doss, Sixel-Dietrich and Verspohl: "Glucose effect" in hepatocytc culture and in acute hepatic porphyrias 509
800
~ ±600
S o81Jj
1 c
2 S, 400
S 2
? g" 200
I I
u
3 ^ !
2 c
§.2α g.
I I
1 2 3 4 5 6 7 8 9 1 0 1 9
t Cdl t IdJ
10 19
Fig. 2. Biochemical response of haem precursor excretion to Fig. 3. Course of the δ-aminolaevulinic acid/porphobilinogen
glucose treatment (400 g/day) in a 15 year old girl with (n) and copro-/uroporphyrin (D) ratios in relation to
acute intermittent porphyria which was exacerbated 9 the biochemical response to glucose outlined in figure
days after mounting doses of valproate up to 600 mg 2.
per day.
version factor ranges over 15, but can drop below
10 in the ascending acute syndrome by excessive
induction of ALA synthase. The conversion rate in-
creases under glucose treatment (tab. 4), because of
ALA synthase repression and therefore reduced ALA
and porphobilinogen formation. The inherited en-
zyme defect in variegate and coproporphyria (fig. 1)
will then become more rate^limiting than the
uroporphyrinogen synthase. The activity of
uroporphyrinogen synthase is not altered under and
after glucose treatment (tab. 4). The activity of this
genetic marker in red bl od cells is relatively constant
within the normal r nge.
In human acute porphyrias the "glucose effect" shows
itself
1. in the significant decrease of urinary ALA,
porphobilinogen and porphyrin excretion (in
variegate and coproporphyria in the fall of faecal
porphyrin too),
2. in the increase of the ALA/porphobilinogen and
copro-/uroporphyrin ratio in acute intermittent
porphyria and
3. in the increase of the liver conversion rate of
porphobilinogen into porphyrin in variegate
porphyria and hereditary coproporphyria.
Tab. 4. Effect of glucose on the conversion rates of porphobilinogen to porphyrins related to erythrocyte uroporphyrinogen
synthase activity (μιηοΐ/ΐ · h; χ ± SEM) in 32 patients with acute intermittent porphyria, hereditary coproporphyria,
variegate porphyria and porphobilinogen syathase defect porphyria. Glucose treatment is defined in table 3.
Diagnosis and cases Uroporphyrinogen synthase
(% of controls)
before and after glucose
* Significance s cornpared to controls: p < 0.001 (Studenfs t-test).
Conversion rate (%)
before and after glucose
Acute intermittent porphyria
(n = 15)
Hereditary coproporphyria
(n = 10)
Variegate porphyria
(n = 5)
Porphob inogen synthase defect
porphyria (n = 2)
Controls (n = 12)
39 ± 5 (52)*
89 ± 5(119)
11 ±2 (102)
81 (108)
75 ± 2 (100)
4Q ±6 (53)*
86 ± 7(115)
80 ± 4 (107)
78 (104)
5.2*
24.5*
8.9
29.9*
9.6
5.5*
90.9*
29.6*
35.0*
10.2
J, Clin. Chem. Clin. Biochem. / Vol. 23,1985 / No. 9
510 Doss, Sixcl-Dietrich and Verspohl: "Glucose effect" in hepatocyte culture and in acute hepatic porphyrias
Discussion
A large number of experimental findings have pro-
vided fundamental evidence that the "glucose-effect"
is of essential importance in therapy and prophylaxis
of acute hepatic porphyrias, and that liver haem
biosynthesis is regulated by the influence of nutri-
tional and hormonal factors (34). In acute hepatic
porphyrias the excessive induction of ALA synthase
äs a counterregulatory mechanism is causally as-
sociated with the development of the clinical
syndrome. Glucose application interferes with ALA
synthase induction and represses enzyme synthesis,
followed by a decrease in the production of ALA,
which possesses neuroinhibitory action (35) and may
be held responsible for the neurologic manifestations
in hereditary acute porphyrias (36) äs well äs in acute
lead intoxication. ALA appeared more toxic to the
neurons than porphobilinogen and other structurally
related amino acids tested, possibly causing a critical
depletion of energy reserves and cell death (37).
Besides glucose, fructose and glycerol (38, 39) also
mediate a decrease of urinary porphyrin precursor
and porphyrin excretion and an improvement of the
clinical course. In our study, however, an increase
of erythrocyte uroporphyrinogen synthase activity
under carbohydrate treatment (39) was not detected.
The metabolic response was consistent in the 32
courses studied (tab. 3) and resulted in a clinical im-
provement in 28 cases. These observations agree with
those of Stein & Tschudy (40) who reported a favor-
able clinical response to glucose in acute intermittent
porphyria. Otherwise the response of different
patients to a high carbohydrate diet varied from
"spectacular clinical improvement" to little effect
(41). There was no explanation for the heterogeneity
of responsiveness, but it has been assumed that
abnormalities in carbohydrate metabolism in acute
intermittent porphyria lead to a decreased glucose
tolerance. Probably gluconeogenesis is stimulated in
acute porphyria syndrome, associated with a decrease
in the insulin-glucagon-ratio. Studies in liver cells
support this assumption, äs the allyl-
isopropylacetamide-induced porphyrin synthesis
depends on a low insulin/glucagon ratio (42), but is
independent under special conditions (20). Individual
variations in the influence of nutritional and
hormonal factors, including the link between sex
hormones and porphyrin metabolism (34) cannot
explain the variations in responsiveness to glucose.
An evaluation of the therapeutic studies (tab. 3) has
clearly shown that clinical response and improvement
are mainly dependent on the clinical condition of the
patieht when glucose treatment is initiated. An early
Start of glucose application is of utmost importance.
At an advanced point of the neurologic syndrome,
when a transition from a functional to a structural
disturbance has already proceeded, most likely under
the neurotoxic effect of ALA, neither glucose nor
haematin (43) can improve the clinical condition iin-
mediately.
In vitro studies on hepatocyte culture
Synthesis of ALA synthase is subject to feedback
regulation by haem (23). In mammalian liver, the
Inhibition by haem appeared to occur mainly at the
posttranscriptional stage (44), although earlier data
includes the possibility that haem also interferes in the
level of transcription (3). Dose response relationships
have shown that increasing amounts of glucose pn>
gressively impair the induction of hepatic ALA
synthase in vivo (38). A similar effect was found in
avian hepatocytes (tab. 1). Other investigators also
demonstrated that the increase of ALA synthase in
vitro by fasting or phenobarbital-mediated induction
can be prevented or diminished by glucose (20, 22).
Fructose, glycerol and lactate mimicked the in-
hibitory glucose effect on ALA synthase whieh is
reversed by 2-deoxyglucose (20). The conversion of
ALA into porphyrin is reflected by the amount of
protoporphyrin synthesized, which represents
70 — 95% of the porphyrin that accürimlates under in
vitro conditions (19, 24), also from added ALA. It
has been concluded that the accumulation of pro-
toporphyrin is due to the limiting activity of
ferrochelatase (16, 19, 45). The normal liver contains
protoporphyrin äs the dominant component (>
70%), thus reflecting its controlled utilization.
In order to increase the conversion of ALA into
porphyrin increasing amounts of ALA were offered
to hepatocyte culture (tab. 2). But the synthesis of
protoporphyrin could not be enhanced. Por-
phobilinogen accumulated and was not metabolized
to porphyrinogen, in analogy with the studies in
homogenates of chick and rat liver (19). Glucose did
not stimulate the conversion of porphobilinogen from
added ALA into porphyrin (tab. 4), suggesting that
uroporphyrinogen synthase is the rate limiting en-
zyme in the haem biosynthetic chain in hepatic haein
synthesis under conditions of high Substrate avail-
ability, i. e. excess of ALA either after induction of
ALA synthase or after ALA supplemeütation. In
the liver, the Vmax of uroporphyrinogen synthase is
probably very close to the Vmax of ALA synthase
°(18). Both enzymes implicate regulatory functions,
but only ALA synthase can be eontrolled by glucose.
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Crucial role öf hepatic uroporphyrinogen
synthase in human
The simultaneously elevated excretion of ALA and
porphobilinogen in acute intermittent porphyria,
coproporphyria and vkriegate porphyria in the acute
crisis is the product of a counterregulatory en-
hancement after induction of liver ALA synthase.
Porphyrin excretion is also increased in all three
conditions, although only acute intermittent
porphyria shows a hereditary uroporphyrinogen
synthase defect (13). These results lead to the theory
of biochemical transition between these three acute
porphyrias (16). The expression of the clinical
Symptoms seems to depend on the unlimited for-
mation (ALA synthase induction) and limited metab-
olism of porphyrin precursors. According to the re-
sults presented here, glucose has an exclusive in-
fluence on the reduction of ALA synthesis but not on
its metabolism to porphobilinogen and porphyrins.
The activity of uroporphyrinogen synthase is very
low. Its Km is approximately 10~6 mol/1 and probably
higher than the normal porphobilinogen con-
centration in the liver, which might be less than l O""6
mol/1 (46). When the porphobilinogen concentration
increases after induction of ALA synthase or after
ALA loading, e. g. to 10~4 mol/1, the activity of
uroporphyrinogen synthase is not sufficient for an
efficient conversion of porphobilinogen into
porphyrin. The step catalysed by uroporphyrinogen
synthase has an apparent "needle-eye-like function".
It has also been described äs a "physiological
bottleneck" (19). This rate limitation becomes path-
ologically severe in conditions of increased Substrate
availability, äs shown by studies in acute intermittent
porphyria patients and after oral ALA loading, both
in controls and in latent acute intermittent porphyria
(31). Under ALA loading in controls (12 mg/kg) the
conversion rate drops from 9 to 3%, and in latent
acute intermittent porphyria from 8 to 4%
demonstrating the limited utilization of por-
phobilinogen by uroporphyrinogen synthase under
Substrate oversäturation. The "physiological
bo.ttleneck" explains the similar increase of both
porphyrin precursors in the three acute porphyrias
and therefore the similafity of abdominal and nervous
Symptoms which are correlated to the increase of
ALA and porphobilinogen (36). Although glucose
has no direct influence on uroporphyrinogen
synthase, the glucose-mediated repression of ALA
synthase indirectly eases the Substrate pressure on
uroporphyrinogen synthase and harmonizes
porphyrin synthesis. As uroporphyrinogen synthase
is not genetically disturbed in variegate and
coproporphyria, diminution of ALA and
porphobilinogen excretion will occur even more
dramatically and faster than in acute intermittent
porphyria with hereditary uroporphyrinogen
synthase defect (tab. 4),
Thoughts on mechanisms u n d e r l y i n g the
glucose effect
The following is an attempt to elaborate a working
hypothesis for the effector mechanism of glucose on
hepatic porphyrias (flg. 4), a phenomenon which is
also mediated by fructose and glycerol. The question
of the "glucose effect" concerns the carbohydrate
repression of enzyme induction, RNA synthesis, and
glucocorticoid activity äs well äs the role of cAMP
and cGMP (20, 47-49). The "glucose effect" seems
to be promoted by intra- and extrahepatic factors in
humans. Glucose äs well äs haem inhibit the drug-
mediated induction of hepatic ALA synthase and the
intracellular t^anslocation of cytosolic to mito-
chondrial ALA synthase (fig. 4). Both the synthesis
and the intracellular translocation of ALA synthase
may be regulated by the Variation of a 'regulatory
haem in a physiological ränge in the liver cell
(44) which is destabilized by hereditary enzymatic
defects (fig. 1) and thereby sensitized to drug action
(13). Depletion of this 'regulatory hepatic haem pooF
in pharmacogenetic diseases like acute hepatic
porphyrias results in a high induction of ALA
synthase (14), which is a counterregulatory event.
Regulation of
hepatic pyrrol, porphyrin
and haem biosynthesis
Fig. 4. The "glucose effect": a hypothetical synopsis shows the
synergism of various hepatic and extrahepatic effector
mechanisms of glucose on the key enzyme of overall
porphyrin and haem biosynthesis, ALA synthase (ALA-
S), in the liver.
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It can be prevented, controlled and suppressed by
glucose. Probably independently of these mech-
anisms, hormonal factors also modulate porphyrin
synthesis in liver: ALA synthase induction is dim-
inished by an increase of the insulin-glucagon-ratio
with consequent lowering of cAMP (26), which may
play a "permissive" role for the induction of ALA
synthase, similar to the effect of glucocorticoids. With
regard to the influence of extrahepatic factors on
hepatic ALA synthase, findings and evidence are con-
troversial and discussed elsewhere (20, 34).
Conclusion
Three points arising from these results should be
stressed:
1. The "glucose effect" on porphyrin synthesis is
reproducible under experimental conditions and
provides ä« national dimension for the high car-
bohydrate treatment of acute hepatic porphyrias.
2. The limiting fünction of uroporphyrinogen
synthase observed in humans under oral ALA
loading äs well äs in acute porphyrias can be
simulated experimentally in hepatocytes in vitro
after induction of ALA synthase and Variation of
the amount of exogenous Al^yV. The relationship
between porphobilinogen and protoporphyrin
concentration is reciprocal and not influenced by
glucose.
3. The "glucose effect" in acute clinical porphyrias
can be considered äs the therapy of choice. Its
efficiency is in no way inferior to that of haematin.
Glucose/fructose may and should be administered
even äs prophylaxis in cases of clinical suspicion.
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